Design Therapeutics, Inc. (DSGN), a clinical-stage biotechnology company, reported first-quarter 2026 financial results and highlighted business updates and upcoming milestones across its GeneTAC portfolio.
Company Profile
Design Therapeutics develops therapies based on its GeneTAC gene-targeted chimaera small molecule platform.
Its lead product candidate, DT-216P2, is designed for the treatment of Friedreich's Ataxia. The development programs also include DT-818 to treat Myotonic Dystrophy Type-1, DT-168 to treat Fuchs Endothelial Corneal Dystrophy and a program for Huntington's Disease.
First Quarter 2026 Results
For the first quarter of 2026, net loss shrank to $17.64 million or $0.29 per share from $17.72 million or $0.31 per share in the prior year.
As of March 31, 2026, the firm had cash, cash equivalents and investment securities of $222.8 million, and it is expected to fund planned operations into 2029.
Milestones Ahead
The firm continues dosing FA patients in its RESTORE-FA trial, a Phase 1/2 multiple-ascending-dose study of DT-216P2 to evaluate safety, pharmacokinetics, and biomarker endpoints.
Design anticipates providing an update on the effect of DT-216P2 on endogenous frataxin levels in the second half of 2026.
In the Myotonic Dystrophy Type-1 (DM1) program for DT-818, the firm expects to begin dosing DM1 patients in its Phase 1 multiple-ascending dose (MAD) trial in the first half of 2026.
DSGN has traded between $3.11 and $13.54 over the last year. The stock closed Wednesday's trade at $12.81.
For More Such Biotech Stock News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
April 24, 2026 15:15 ET Economics news flow was relatively light this week even as the conflict in the Middle East continued, raising concerns for policymakers. In the U.S., spending data, initial jobless claims and pending home sales were the highlights. Business confidence in the biggest euro area economy was in focus in Europe. Inflation data from Japan gained attention in Asia.